Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of irinotecan + anlotinib in first recurrent glioblastoma
ChiCTR1900023462Phase 4Recruiting
- Sponsor
- Tianjin Huanhu Hospital
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan and anlotinib in glioblastoma (GBM), sponsored by Tianjin Huanhu Hospital. Primary endpoint: 6-month progression-free survival. Started Jun 2019; status: recruiting.
02
Drugs
irinotecananlotinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR1900023462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023462.